Previous studies indicated that low LKB1 expression was related to a significantly shorter OS and led to inferior therapeutic responsiveness to pembrolizumab in patients with GC, suggesting that LKB1 might be a potential immunotherapeutic target41. This evidence concerns the gene STK11 and gastric cancer.